Literature DB >> 1993012

Alterations in brain phosphate metabolite concentrations in patients with human immunodeficiency virus infection.

R F Deicken1, B Hubesch, P C Jensen, D Sappey-Marinier, P Krell, A Wisniewski, D Vanderburg, R Parks, G Fein, M W Weiner.   

Abstract

Human immunodeficiency virus (HIV)-infected individuals often demonstrate neuropsychiatric impairment; however, it is unclear how brain metabolism may be altered in such patients. We used in vivo phosphorus 31 magnetic resonance spectroscopy to noninvasively assess brain energy and phospholipid metabolism by measuring brain concentrations of adenosine triphosphate (ATP), phosphocreatine (PCr), and inorganic phosphate (Pi), as well as phospholipid compounds and intracellular pH. In study 1, 17 HIV-seropositive men with varying degrees of neuropsychiatric impairment and six control subjects were studied. Localized spectra were obtained from a heterogeneous 5 x 5 x 5-cm volume of interest (VOI). Patients with HIV infection had a significantly lower ATP/Pi ratio and a trend for a lower PCr/Pi ratio than did the control group. In addition, the ATP/Pi and PCr/Pi ratios were both significantly negatively correlated with overall severity of neuropsychiatric impairment. In study 2, three HIV-seropositive men with neuropsychiatric impairment were compared with 11 HIV-seronegative men. Localized phosphorus 31 magnetic resonance spectra were obtained from two relatively homogeneous VOIs: (1) a predominantly white matter VOI, and (2) a predominantly subcortical gray matter VOI. The three HIV-infected patients demonstrated significantly decreased ATP and PCr concentrations in the white matter VOI. These results suggest that HIV infection of the brain may impair brain cellular oxidative metabolism and that the degree of metabolic compromise may be related to the severity of neuropsychiatric impairment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1993012     DOI: 10.1001/archneur.1991.00530140099022

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  8 in total

Review 1.  The role of medical imaging in defining CNS abnormalities associated with HIV-infection and opportunistic infections.

Authors:  David F Tate; Rola Khedraki; Daniel McCaffrey; Daniel Branson; Jeffrey Dewey
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

2.  Neuronal glycolytic pathway impairment induced by HIV envelope glycoprotein gp120.

Authors:  A L Vignoli; I Martini; K G Haglid; L Silvestroni; G Augusti-Tocco; S Biagioni
Journal:  Mol Cell Biochem       Date:  2000-12       Impact factor: 3.396

Review 3.  Neuropsychiatric aspects of HIV infection.

Authors:  I P Everall
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-04       Impact factor: 10.154

4.  Acute diffuse leukoencephalitis in HIV-1 infection.

Authors:  W Lüer; J Gerhards; S Poser; T Weber; K Felgenhauer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-01       Impact factor: 10.154

Review 5.  What might be the impact on neurology of the analysis of brain metabolism by in vivo magnetic resonance spectroscopy?

Authors:  J Vion-Dury; D J Meyerhoff; P J Cozzone; M W Weiner
Journal:  J Neurol       Date:  1994-05       Impact factor: 4.849

Review 6.  Some methodological issues in neuroradiological research in psychiatry.

Authors:  T Becker; W Retz; E Hofmann; G Becker; E Teichmann; W Gsell
Journal:  J Neural Transm Gen Sect       Date:  1995

7.  Gene expression changes consistent with neuroAIDS and impaired working memory in HIV-1 transgenic rats.

Authors:  Vez Repunte-Canonigo; Celine Lefebvre; Olivier George; Tomoya Kawamura; Marisela Morales; George F Koob; Andrea Califano; Eliezer Masliah; Pietro Paolo Sanna
Journal:  Mol Neurodegener       Date:  2014-07-01       Impact factor: 14.195

8.  Metabolic Reprogramming in HIV-Associated Neurocognitive Disorders.

Authors:  Charles N S Allen; Sterling P Arjona; Maryline Santerre; Claudio De Lucia; Walter J Koch; Bassel E Sawaya
Journal:  Front Cell Neurosci       Date:  2022-03-28       Impact factor: 5.505

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.